Our recent study to extend the results using NOJ mice engrafted with shPromA-transduced CD34+ cells and their derivatives further demonstrated that PromA could be an effective gene therapy for protecting bone marrow CD34+ cells and the hematopoietic potential of the host from HIV infection (Figure 3) [26]. This evidence concerns the gene CD34 and HIV infectious disease.